Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Elevidys

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.

MarketBeat

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy

The Independent UK

Stock Market Indexes In Range But Leaders Flash Buy Signals Amid Trump Trade Deal: Weekly Review

The major indexes are still rangebound, but picked up on a Trump trade deal with the U.K. Many leaders flashed buy signals.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low

Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.

Investors Business Daily

Can Solid Biosciences Challenge Sarepta in the DMD Market?

Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.

MarketBeat

Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy

Sarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.

Investors Business Daily

Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.

Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The three-horse race to treat a devastating form of muscular dystrophy is now down to two. And Avidity Biosciences is feeling bullish.

Investors Business Daily

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

Sarepta will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has taken a beating since its last report.

Investors Business Daily

Sarepta Crashes 37% After Its Gene Therapy Flops Its Biggest-Ever Test

Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Palantir Technologies

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.